EP1233979A1 - Method of diagnosing neurodegenerative disease - Google Patents

Method of diagnosing neurodegenerative disease

Info

Publication number
EP1233979A1
EP1233979A1 EP00982134A EP00982134A EP1233979A1 EP 1233979 A1 EP1233979 A1 EP 1233979A1 EP 00982134 A EP00982134 A EP 00982134A EP 00982134 A EP00982134 A EP 00982134A EP 1233979 A1 EP1233979 A1 EP 1233979A1
Authority
EP
European Patent Office
Prior art keywords
acetylcholine receptor
nicotinic acetylcholine
test sample
receptor protein
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00982134A
Other languages
German (de)
French (fr)
Inventor
Daniel H. S. Lee
Allen B. Reitz
Carlos R. Plata-Salaman
Hoau-Yan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of EP1233979A1 publication Critical patent/EP1233979A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • AD Alzheimer's disease
  • PD Parkinson's disease
  • AD is characterized by neurofibrillary tangles, neuritic plaques, and neuronal cell death.
  • AD appears as either the familial, early onset or late-onset forms, with the latter being more prevalent.
  • AD is the major cause of age-related dementia and cognitive impairment (Wisniewski, T. ; Ghiso, J. ; Frangione, B. Neurobiol . of Disease 1997, 4, 313-328).
  • the only effective diagnostic method consists of cognitive function of the patient. There is a need to develop sensitive, biochemical methods to determine the prognosis, progression, and monitor therapeutic efficacy of subjects likely to develop or suffering from Alzheimer's disease.
  • the neurotoxic ⁇ -amyloid peptide 1-4 [A ⁇ _4 2 ] is abundantly present in the amyloid plaques of Alzheimer's disease (AD) brains and also modulates cholinergic functions which are critical in memory and cognitive neurophysiology (Auld, D.S., Kar, S., Quirion, R. Trends Neurosci 1998; 21: 43-49).
  • a ⁇ ,. ⁇ interacts selectively and with high affinity to the neuronal pentameric cation channel ⁇ 7 nicotinic acetylcholine receptor (Wang, H.-Y. et al . J. Biol . Chem. 2000, in press) .
  • nAChRs nicotinic acetylcholine receptors
  • compounds that activate nAChRs, especially of the alpha-7 subtype have been found to have in vivo activity in models of cognition enhancement (US Patent No. 5,741,802, issued April 21, 1998).
  • Beta-amyloid peptide increases cytosolic-free Ca 2+ in AD lymphoblasts (Ibarreta et al . , Alzheimer Di ⁇ Assoc Disord 1997 Dec; 11 (4) :220-7) , and elevates mitogen- induced Ca 2+ responses in freshly prepared human lymphocytes (Eckert et al . , Life Sci 1994;55 (25-26) :2019-29) .
  • Amyloid precursor protein can be induced on the cell surface of human lymphocytes upon stimulation (Bullido et al . , Biochim Biophys Acta 1996 Aug 21;1313 (1) :54-62) and increased APP-770 isoform occurs in lymphocytes from AD patients (Ebstein et al., Brain Res Mol Brain
  • ymphoblastoid cells from patients with early-onset and late-onset familial AD show increased expression of APP mRNA and protein (Matsumot ⁇ et al . , Eur J Biochem 1993 Oct 1;217(1) :21-7) .
  • the interaction of the ⁇ 7 nicotinic acetylcholine receptor may initiate a series of pathophysiological events observed in AD leading to neurotoxicity and contribute to cognitive dysfunction, a hallmark of ADInvestigators have measured ⁇ 7 nicotinic acetylcholine receptor mRNA levels in normal and AD subjects' brains in order to determine changes in regional distribution or changes in the total amount of mRNA levels between the subject populations.
  • ⁇ 7 nicotinic acetylcholine receptor mRNA was equally distributed in all areas of the brain except the hippocampus, where AD subjects exhibited higher mRNA levels than the control population.
  • lymphocytes from AD patients exhibit an increased mRNA level for ⁇ 7 nicotinic acetylcholine receptor (Hellstrom-Lindahl et al.. Brain Res Mol Brain Res 1999 Mar 20;66 (1-2) : 94-103) .
  • nicotinic acetylcholine receptor binding in brains of AD and control subjects showed no significant difference (Lang, W. and Henke, H. Brain Res 1983; 267: 271-280).
  • the present invention provides the unexpected observation that ⁇ 7 nicotinic acetylcholine receptor protein levels are decreased in neuronal tissue, thus forming the basis of a biochemical assay to diagnose Alzheimer's disease. Summary of the invention
  • the present invention provides methods for diagnosing Alzheimer's disease, monitoring the progression and prognosis of Alzheimer's disease and/or monitoring the therapeutic efficacy of any intervention or treatment of Alzheimer's disease comprising:
  • test sample comprises a cell, said cell expressing ⁇ 7 nicotinic acetylcholine receptor protein;
  • test sample comprises a cell, said cell expressing ⁇ 7 nicotinic acetylcholine receptor protein;
  • FIG. 1 ⁇ 7 nicotinic acetylcholine receptor protein levels in Alzheimer's disease (AD) brains are reduced. Equal amounts of hippocampal proteins from AD or control subjects were subjected to electrophoresis and Western blot analysis using anti- ⁇ 7 nicotinic acetylcholine receptor antibodies . The intensity of the bands was measured by densitometry . Representative data from three AD [Al-3] and control [Cl-3] are shown. Molecular weight markers in kiloDalton are shown.
  • the present invention also provides tools useful for diagnosing
  • Alzheimer's disease exhibits neuropathological abnormalities in the olfactory system located in the nasal cavity. These include the presence of dystrophic neurites that exhibit i munoreactivity for tau, neurofilaments, apolipoprotein E and other proteins, abnormal tau protein, increase in superoxide dismutase, and ⁇ amyloid deposition in the primary sensory (olfactory receptor) cells and nerve fibres of the nasal ucosa tissue (Arnold et al., Ann N Y Acad Sci 1998 Nov 30;855:762-75; Hock et al .
  • Olfactory neuroblasts olfactory neurons obtained by biopsy and placed in primary cell culture
  • AD patients produce carboxyl terminal amyloid precursor protein (APP) fragments that contain ⁇ amyloid (A ⁇ )
  • APP carboxyl terminal amyloid precursor protein
  • a ⁇ ⁇ amyloid
  • Crino et al . showed labeling of A ⁇ in the basal third of the olfactory neuroepithelium and in axons projecting through the lamina intestinal of AD patients .
  • Thioflavin-S staining that detects amyloid deposition was also observed in the basal third of the olfactory neuroepithelium from AD patients.
  • ⁇ 7 nicotinic acetylcholine receptors are present in olfactory neurons probably including olfactory receptor cells in the nasal cavity (Alkondon et al., Neurosci Lett 1994 Aug 1; 176 (2) : 152-6; Alkondon et al . , Eur J Neurosci 1997 Dec; 9 (12) :2734-42 ; Bouvet et al . , Neurosci Res 1988 Feb;5 (3) :214-23; Edwards et al .
  • Lymphocytes including B cells, T cells and neutrophils
  • Lymphocytes also likely express ⁇ 7 nicotinic acetylcholine receptor protein, though evidence of such expression is indirect via the observation of Beta- amyloid peptide functional activity in AD patients (Ibarreta et al, Ekert et al) or by measurement of mRNA (Hellstom-Lindahl et al) .
  • test sample comprises a cell
  • the inventors further contemplate that the ⁇ 7 nicotinic acetylcholine receptor protein may be increased in some tissues or cell types, while decreased in others. Further, the inventors contemplate that ⁇ 7 nicotinic acetylcholine receptor protein may be sequestered within the cell, and that intracellular ⁇ 7 nicotinic acetylcholine receptor protein may be increased in AD subjects. As previously noted, the quantity of mRNA is apparently distinct from the protein levels in any particular cell type.
  • the analysis of the changes in the level of ⁇ 7 nicotinic acetylcholine receptor protein in lymphocytes and olfactory neuroepithelial neurons/neuronal processes or olfactory neuroblasts obtained from AD patients can be used as an AD diagnostic marker, useful for AD prognosis, progression, and therapeutic efficacy of any intervention or treatment targeting AD.
  • the present invention provides the unexpected observation that the ⁇ 7 nicotinic acetylcholine receptor protein is down-regulated in hippocampal tissue of AD subjects, rather than unregulated, as has been observed in the mRNA levels for the ⁇ 7 nicotinic acetylcholine receptor gene.
  • the present invention provides methods for diagnosing
  • Alzheimer's disease monitoring the prognosis and progression of Alzheimer's disease and monitoring the therapeutic efficacy of any intervention or treatment of Alzheimer's disease comprising:
  • test sample comprises a cell, said cell expressing ⁇ 7 nicotinic acetylcholine receptor protein;
  • sample refers to any substance that may contain ⁇ 7 nicotinic acetylcholine receptor protein.
  • a sample can be biological fluid, such as whole blood or whole blood components including red blood cells, white blood cells, platelets, serum and plasma, ascites, urine, cerebrospinal fluid, and other constituents of the body that may contain the cell or fragment containing ⁇ 7 nicotinic acetylcholine receptor protein.
  • a sample may be a component in a larger composition, for example in a tissue section of a biopsy, where the cells of interest may belong to one or more cellular subtypes amongst a field of different cell types.
  • cell refers to at least one cell, but includes a plurality of cells, or fractions of cells appropriate for the sensitivity of the detection method.
  • Cells suitable for the present invention may be present as isolated, purified cell populations or as a fraction of an organized tissue biopsy. Fractions of cells, including the axon or dendrites of a neuron are also suitable for use in the present invention, and may be isolated, for example in a tissue section of a biopsy.
  • Preferred cells suitable for use in the present invention are selected from the group consisting of circulating lymphocytes, olfactory neuroepithelial neuronal cell bodies or their neuronal processes, or hippocampal cells.
  • compound capable of specific interaction with the ⁇ 7 nicotinic acetylcholine receptor refers to, for example, synthetic or natural amino acid polypeptides, proteins, small synthetic organic molecules, or deoxy- or ribo- nucleic acid sequences that bind to the ⁇ 7 nicotinic acetylcholine receptor with about 20-fold or greater affinity compared to other proteins.
  • a ⁇ 1-40 , A ⁇ 1-42 , A ⁇ - 3 , peptides, purified from natural sources or created synthetically using peptide synthetic methods, polyclonal or monoclonal antibodies raised against the ⁇ 7 nicotinic acetylcholine receptor, or a peptide fragment thereof, or small organic molecules that block A ⁇ 1-40 ⁇ A ⁇ 1-42 , A ⁇ ⁇ - « peptide interaction with the receptor are suitable for use in the present invention.
  • Preferred compounds of the present invention include A ⁇ 1-40 ⁇ A ⁇ 1-42 , A ⁇ 1-43 peptides, or antibodies that bind to the a7 nicotinic acetylcholine receptor.
  • Compounds useful in the present invention may be labeled compounds, with means of direct detection, or may be detected by an indirect means, for example by a second labeled compound.
  • labeled compound refers to moieties capable of measurement comprising radioactive atoms, enzymes, fluorescent molecules, or alternative tags, for example biotin.
  • radioisotopes useful as a label in the present invention are 3 H, 15 I, 131 I, 35 S, 32 P, or 33 P and others that can be applied in brain imaging analyses.
  • Particular examples of enzymes suitable for use in the present invention are horseradish peroxidase, alkaline pho ⁇ phatase, or luciferase.
  • a preferred example of a detectable label is an enzyme that cleaves a substrate to yield a chromogenic or luminescent product.
  • fluorescent molecules are fluorescein (FITC) , rhodamine, or AlexaTM dyes (Molecular Probes) .
  • Direct measurement is conducted by observing the presence of the radioactive atom or flourogenic molecule, or by observation of enzymatic activity of a colorimetric or luminescent substrate.
  • Indirect measurement is conducted by adding an additional compound including a label to the test sample so that it can interact with the compound bound to the test sample.
  • the labeled compound comprises biotin
  • a second compound comprises avidin or streptavidin and a detectable label.
  • a second well-known example is when a first antibody is used to bind to the ⁇ 7 nicotinic acetylcholine receptor and is detected with a second anti-antibody comprising a detectable label.
  • the first antibody comprises a label in that there are specific regions capable of detection within the structure of the first antibody.
  • the level of ⁇ 7 nicotinic acetylcholine receptor protein can be assessed by measuring its direct binding to the labeled compound.
  • the level of ⁇ 7 nicotinic acetylcholine receptor protein can be assessed by measuring the binding of labeled ⁇ 7 nicotinic acetylcholine receptor protein or an analogue which competes for binding with ⁇ 7 nicotinic acetylcholine receptor protein to an unlabeled compound that interacts with ⁇ 7 nicotinic acetylcholine receptor protein.
  • the method of the present invention can be further defined by adding a step (d) of comparing changes in the level of ⁇ 7 acetylcholine protein in the test sample with an established normal level determined by measuring the ct7 nicotinic acetylcholine receptor protein in an normal samples.
  • Normal sample refers to a sample from a subject who demonstrates no detectable neurodegenerative disease, for example, Alzheimer's disease, by known cognitive diagnostic methods, and may include preserved tissue sections from tissue archives.
  • the measurement means of step (c) suitable for the method of the present invention comprises measuring changes in the quantity of intracellular protein, or cell surface protein. Immunoaffinity or ligand affinity measurement quantitates levels of protein in or on the surface of host cells.
  • Unlabelled ⁇ 7 nicotinic acetylcholine receptor protein is detected by Western blotting, cell surface detection by fluorescent cell sorting, cell image analysis, and immunoassay employing compounds specific for ⁇ 7 nicotinic acetylcholine receptor protein.
  • Preferred detection means for cell surface protein include flow cytometry or statistical cell imaging. In both techniques the protein of interest is localized at the cell surface, labeled with a specific fluorescent probe, and detected via the degree of cellular fluorescence. In flow cytometry, the cells are analyzed in a solution, whereas in cellular imaging techniques, a field of cells is compared for relative fluorescence.
  • the methods of the present invention may be used to measure intracellular ⁇ 7 nicotinic acetylcholine receptor protein contained within the entoplasmic reticulum, Golgi complex, or vesicles.
  • This method provides that the test sample be pretreated to perforate the cell membranes or to solubilize the cell, for example with a detergent containing solution, both techniques are well known in the art.
  • the compound enters the cell and specifically interacts with the cc7 nicotinic acetylcholine receptor in the compartments previously described.
  • Cell extracts provide soluble ⁇ 7 nicotinic acetylcholine receptor protein that may be measured by the methods described herein, preferably by ELISA utilizing a chemiluminescent detection system.
  • the method to detect intracellular ⁇ 7 nicotinic acetylcholine receptor protein comprises the steps: (a) obtaining a test sample from a subject wherein the test sample comprises a cell, said cell expressing ⁇ 7 nicotinic acetylcholine receptor protein in healthy individuals;
  • Membrane perforating agents are well known in the art, and are used, for instance to perforate lymphocytic cells to analyze intracellular components using flow cytometry. These agents are commercially available, for example, by Ortho Clinical
  • a particular assay of the present invention comprises binding protein assay methods using a compound capable of specific interaction with ⁇ 7 nicotinic acetylcholine receptor protein to detect changes in the level of 7 nicotinic acetylcholine receptor protein.
  • the compound is an antibody to ⁇ 7 nicotinic acetylcholine receptor protein.
  • the preferred method to detect ⁇ 7 nicotinic acetylcholine receptor protein comprises the steps: (a) obtaining a test sample from a subject wherein the test sample comprises a cell, said cell expressing ⁇ 7 nicotinic acetylcholine receptor protein in healthy individuals;
  • Particular changes in the level of the oc7 nicotinic acetylcholine receptor protein are either to increase or to decrease in the test sample.
  • the preferred change in the level of the ⁇ 7 nicotinic acetylcholine receptor protein in lymphocytes, olfactory tissue, and hippocampal tissue is to decrease as an indication of development or worsening of AD in the subject.
  • Figure 1 shows that the amount of ⁇ 7 nicotinic acetylcholine receptor protein was reduced. The extent of the reduction was measured by densitometry and indicated that the ⁇ 7 acetylcholine receptor was reduced by 57+5% compared to controls (Table 1, p ⁇ 0.04). A reduction was observed in all twelve AD brain samples tested.
  • Postmortem brains were obtained from Harvard Brain Tissue Resource Center at McLean Hospital (Belmont, MA) and Analytical Biological Services, Inc. (Wilmington, DE).
  • the mean ages of the subjects for AD and controls were 73.9 ⁇ 1.5 and 71.6 ⁇ 1.4, respectively.
  • the postmortem interval for AD and control subjects were 11.7 ⁇ 1.4 hr and 10.0 ⁇ 2.0 hr, respectively.

Abstract

The present invention provides methods for diagnosing neurodegenerative disease such as Alzheimer's disease, monitoring the progression and prognosis of the disease and/or monitoring the therapeutic efficacy of any intervention or treatment of the disease comprising measuring the level of α7 nicotinic acetylcholine receptor protein.

Description

METHOD OF DIAGNOSING NEURODEGENERATIVE DISEASE
Background of the Invention Neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD) afflict humanity with great suffering and financial loss. AD is characterized by neurofibrillary tangles, neuritic plaques, and neuronal cell death. AD appears as either the familial, early onset or late-onset forms, with the latter being more prevalent. AD is the major cause of age-related dementia and cognitive impairment (Wisniewski, T. ; Ghiso, J. ; Frangione, B. Neurobiol . of Disease 1997, 4, 313-328). Currently the only effective diagnostic method consists of cognitive function of the patient. There is a need to develop sensitive, biochemical methods to determine the prognosis, progression, and monitor therapeutic efficacy of subjects likely to develop or suffering from Alzheimer's disease.
The neurotoxic β-amyloid peptide1-4 [Aβι_42] is abundantly present in the amyloid plaques of Alzheimer's disease (AD) brains and also modulates cholinergic functions which are critical in memory and cognitive neurophysiology (Auld, D.S., Kar, S., Quirion, R. Trends Neurosci 1998; 21: 43-49). Aβ,.^ interacts selectively and with high affinity to the neuronal pentameric cation channel α7 nicotinic acetylcholine receptor (Wang, H.-Y. et al . J. Biol . Chem. 2000, in press) . This peptide-receptor interaction is likely neurotoxic due to the observation that stimulation of the alpha-7 subtype of the nicotinic acetylcholine receptors (nAChRs) can protect neurons against Aβ cytotoxicity (Kihara, T. et al. Ann. JVeurol. 1997, 42, 159). Also, compounds that activate nAChRs, especially of the alpha-7 subtype, have been found to have in vivo activity in models of cognition enhancement (US Patent No. 5,741,802, issued April 21, 1998). The α7 nicotinic acetylcholine receptor is involved in calcium homeostasis and modulation of acetylcholine release in the synapses, all of which are critical events leading to memory formation. Beta-amyloid peptide increases cytosolic-free Ca2+ in AD lymphoblasts (Ibarreta et al . , Alzheimer Diε Assoc Disord 1997 Dec; 11 (4) :220-7) , and elevates mitogen- induced Ca2+ responses in freshly prepared human lymphocytes (Eckert et al . , Life Sci 1994;55 (25-26) :2019-29) . Amyloid precursor protein (APP) can be induced on the cell surface of human lymphocytes upon stimulation (Bullido et al . , Biochim Biophys Acta 1996 Aug 21;1313 (1) :54-62) and increased APP-770 isoform occurs in lymphocytes from AD patients (Ebstein et al., Brain Res Mol Brain
Res 1996 Jan;35 (1-2) :260-8) . ymphoblastoid cells from patients with early-onset and late-onset familial AD show increased expression of APP mRNA and protein (Matsumotσ et al . , Eur J Biochem 1993 Oct 1;217(1) :21-7) . The interaction of the α7 nicotinic acetylcholine receptor may initiate a series of pathophysiological events observed in AD leading to neurotoxicity and contribute to cognitive dysfunction, a hallmark of ADInvestigators have measured α7 nicotinic acetylcholine receptor mRNA levels in normal and AD subjects' brains in order to determine changes in regional distribution or changes in the total amount of mRNA levels between the subject populations. α7 nicotinic acetylcholine receptor mRNA was equally distributed in all areas of the brain except the hippocampus, where AD subjects exhibited higher mRNA levels than the control population. Similarly, lymphocytes from AD patients exhibit an increased mRNA level for α 7 nicotinic acetylcholine receptor (Hellstrom-Lindahl et al.. Brain Res Mol Brain Res 1999 Mar 20;66 (1-2) : 94-103) . In a second report, nicotinic acetylcholine receptor binding in brains of AD and control subjects showed no significant difference (Lang, W. and Henke, H. Brain Res 1983; 267: 271-280). The present invention provides the unexpected observation that α7 nicotinic acetylcholine receptor protein levels are decreased in neuronal tissue, thus forming the basis of a biochemical assay to diagnose Alzheimer's disease. Summary of the invention
The present invention provides methods for diagnosing Alzheimer's disease, monitoring the progression and prognosis of Alzheimer's disease and/or monitoring the therapeutic efficacy of any intervention or treatment of Alzheimer's disease comprising:
(a) obtaining a test sample from a subject wherein the test sample comprises a cell, said cell expressing α7 nicotinic acetylcholine receptor protein; (b) contacting the test sample with a compound capable of specific interaction with the cc7 nicotinic acetylcholine receptor protein; and
(c) measuring the binding of the compound to α7 nicotinic acetylcholine receptor protein as an indication of α7 nicotinic acetylcholine receptor protein in the test sample.
Brief description of the drawings
Figure 1. α7 nicotinic acetylcholine receptor protein levels in Alzheimer's disease (AD) brains are reduced. Equal amounts of hippocampal proteins from AD or control subjects were subjected to electrophoresis and Western blot analysis using anti-α7 nicotinic acetylcholine receptor antibodies . The intensity of the bands was measured by densitometry . Representative data from three AD [Al-3] and control [Cl-3] are shown. Molecular weight markers in kiloDalton are shown.
Detailed description of the invention
The present invention also provides tools useful for diagnosing
Alzheimer's disease. Among other tissues, Alzheimer's disease (AD) exhibits neuropathological abnormalities in the olfactory system located in the nasal cavity. These include the presence of dystrophic neurites that exhibit i munoreactivity for tau, neurofilaments, apolipoprotein E and other proteins, abnormal tau protein, increase in superoxide dismutase, and β amyloid deposition in the primary sensory (olfactory receptor) cells and nerve fibres of the nasal ucosa tissue (Arnold et al., Ann N Y Acad Sci 1998 Nov 30;855:762-75; Hock et al . , Eur Neurol 1998 Jul; 40 (1) : 31-6 ; Johnson et al., JVeurobiol Aging 1994 Nov-Dec;15 (6) :675-80; Kulkarni-Narla et al., Exp Neurol 1996 Aug;140 (2) : 115-25; Lee et al . , Exp Neurol 1993 May;121(l) :93-105; Tabaton et al . , Neurology 1991 Mar; 41 (3) :391-4 ;
Talamo et al . , Ann N Y Acad Sci 1991;640:1-7; Yamagiεhi et al . , Ann Otol Rhinol Laryngol 1998 May;107(5 Pt l):421-6; Ya agishi et al . , Nippon Jibiinkoka Gakkai Kaiho 1994 Jan; 97 (1) :51-60) . These observations recapitulate the neuropathological profile and neurodegenerative abnormalities (e.g., cytoskeletal changes, protein immunoreactivity and β amyloid deposition) observed in central nervous system neurons from AD patients. Routine access to these sensory neurons and fibers can be done with nasal biopsy in AD patients (e.g., Feron et al . , Arch Otolaryngol Head Neck Surg 1998 Aug;124 (8) :861-6) .
Olfactory neuroblasts (olfactory neurons obtained by biopsy and placed in primary cell culture) from AD patients produce carboxyl terminal amyloid precursor protein (APP) fragments that contain β amyloid (Aβ) (Crino et al . , Ann Otol Rhinol Laryngol 1995 Aug;104 (8) :655-61) . Crino et al . showed labeling of Aβ in the basal third of the olfactory neuroepithelium and in axons projecting through the lamina propria of AD patients . Thioflavin-S staining that detects amyloid deposition was also observed in the basal third of the olfactory neuroepithelium from AD patients. α7 nicotinic acetylcholine receptors are present in olfactory neurons probably including olfactory receptor cells in the nasal cavity (Alkondon et al., Neurosci Lett 1994 Aug 1; 176 (2) : 152-6; Alkondon et al . , Eur J Neurosci 1997 Dec; 9 (12) :2734-42 ; Bouvet et al . , Neurosci Res 1988 Feb;5 (3) :214-23; Edwards et al . , Experi entia 1987 Aug 15;43 (8) : 868- 73; Edwards et al., Experi entia 1988 Mar 15;44 (3) :208-ll; Seguela et al., J" Neurosci 1993 Feb; 13 (2) :596-604) .
Lymphocytes (including B cells, T cells) and neutrophils, also likely express α7 nicotinic acetylcholine receptor protein, though evidence of such expression is indirect via the observation of Beta- amyloid peptide functional activity in AD patients (Ibarreta et al, Ekert et al) or by measurement of mRNA (Hellstom-Lindahl et al) . The inventors contemplate that numerous clinically available tissues express α7 nicotinic acetylcholine receptor, which can be easily determined by a method comprising:
(a) obtaining a test sample from a subject wherein the test sample comprises a cell;
(b) contacting the test sample with a compound capable of specific interaction with the α7 nicotinic acetylcholine receptor; and
(c) measuring binding of the compound to the test sample.
The inventors further contemplate that the α7 nicotinic acetylcholine receptor protein may be increased in some tissues or cell types, while decreased in others. Further, the inventors contemplate that α7 nicotinic acetylcholine receptor protein may be sequestered within the cell, and that intracellular α7 nicotinic acetylcholine receptor protein may be increased in AD subjects. As previously noted, the quantity of mRNA is apparently distinct from the protein levels in any particular cell type.
The analysis of the changes in the level of α7 nicotinic acetylcholine receptor protein in lymphocytes and olfactory neuroepithelial neurons/neuronal processes or olfactory neuroblasts obtained from AD patients can be used as an AD diagnostic marker, useful for AD prognosis, progression, and therapeutic efficacy of any intervention or treatment targeting AD. The present invention provides the unexpected observation that the α7 nicotinic acetylcholine receptor protein is down-regulated in hippocampal tissue of AD subjects, rather than unregulated, as has been observed in the mRNA levels for the α7 nicotinic acetylcholine receptor gene. The present invention provides methods for diagnosing
Alzheimer's disease, monitoring the prognosis and progression of Alzheimer's disease and monitoring the therapeutic efficacy of any intervention or treatment of Alzheimer's disease comprising:
(a) obtaining a test sample from a subject wherein the test sample comprises a cell, said cell expressing α7 nicotinic acetylcholine receptor protein;
(b) contacting the test sample with a compound capable of specific interaction with the α7 nicotinic acetylcholine receptor protein; and (c) measuring the binding of the compound to α7 nicotinic acetylcholine receptor protein as an indication of α7 nicotinic acetylcholine receptor protein in the test sample.
A "sample" as used herein, refers to any substance that may contain α7 nicotinic acetylcholine receptor protein. A sample can be biological fluid, such as whole blood or whole blood components including red blood cells, white blood cells, platelets, serum and plasma, ascites, urine, cerebrospinal fluid, and other constituents of the body that may contain the cell or fragment containing α7 nicotinic acetylcholine receptor protein. Further, a sample may be a component in a larger composition, for example in a tissue section of a biopsy, where the cells of interest may belong to one or more cellular subtypes amongst a field of different cell types.
The term "cell" refers to at least one cell, but includes a plurality of cells, or fractions of cells appropriate for the sensitivity of the detection method. Cells suitable for the present invention may be present as isolated, purified cell populations or as a fraction of an organized tissue biopsy. Fractions of cells, including the axon or dendrites of a neuron are also suitable for use in the present invention, and may be isolated, for example in a tissue section of a biopsy. Preferred cells suitable for use in the present invention are selected from the group consisting of circulating lymphocytes, olfactory neuroepithelial neuronal cell bodies or their neuronal processes, or hippocampal cells.
The phrase "compound capable of specific interaction with the α7 nicotinic acetylcholine receptor" refers to, for example, synthetic or natural amino acid polypeptides, proteins, small synthetic organic molecules, or deoxy- or ribo- nucleic acid sequences that bind to the α7 nicotinic acetylcholine receptor with about 20-fold or greater affinity compared to other proteins. For example, but not by way of limitation, Aβ1-40, Aβ1-42, Aβι- 3, peptides, purified from natural sources or created synthetically using peptide synthetic methods, polyclonal or monoclonal antibodies raised against the α7 nicotinic acetylcholine receptor, or a peptide fragment thereof, or small organic molecules that block Aβ1-40ι Aβ1-42, Aβι-« peptide interaction with the receptor are suitable for use in the present invention. Preferred compounds of the present invention include Aβ1-40ι Aβ1-42, Aβ1-43 peptides, or antibodies that bind to the a7 nicotinic acetylcholine receptor. Compounds useful in the present invention may be labeled compounds, with means of direct detection, or may be detected by an indirect means, for example by a second labeled compound. The phrase "labeled compound" refers to moieties capable of measurement comprising radioactive atoms, enzymes, fluorescent molecules, or alternative tags, for example biotin. Particular radioisotopes useful as a label in the present invention are 3H, 15I, 131I, 35S, 32P, or 33P and others that can be applied in brain imaging analyses. Particular examples of enzymes suitable for use in the present invention are horseradish peroxidase, alkaline phoεphatase, or luciferase. A preferred example of a detectable label is an enzyme that cleaves a substrate to yield a chromogenic or luminescent product. Particular examples of fluorescent molecules are fluorescein (FITC) , rhodamine, or Alexa™ dyes (Molecular Probes) . Direct measurement is conducted by observing the presence of the radioactive atom or flourogenic molecule, or by observation of enzymatic activity of a colorimetric or luminescent substrate. Indirect measurement is conducted by adding an additional compound including a label to the test sample so that it can interact with the compound bound to the test sample. A well- known example is when the labeled compound comprises biotin, and a second compound comprises avidin or streptavidin and a detectable label. A second well-known example is when a first antibody is used to bind to the α7 nicotinic acetylcholine receptor and is detected with a second anti-antibody comprising a detectable label. In this case the first antibody comprises a label in that there are specific regions capable of detection within the structure of the first antibody.
The level of α7 nicotinic acetylcholine receptor protein can be assessed by measuring its direct binding to the labeled compound. Alternatively the level of α7 nicotinic acetylcholine receptor protein can be assessed by measuring the binding of labeled α7 nicotinic acetylcholine receptor protein or an analogue which competes for binding with α7 nicotinic acetylcholine receptor protein to an unlabeled compound that interacts with α7 nicotinic acetylcholine receptor protein. These and other methods for immunoaffinity or ligand affinity measurements are well known to those skilled in the art.
The method of the present invention can be further defined by adding a step (d) of comparing changes in the level of α7 acetylcholine protein in the test sample with an established normal level determined by measuring the ct7 nicotinic acetylcholine receptor protein in an normal samples. "Normal sample" as used herein refers to a sample from a subject who demonstrates no detectable neurodegenerative disease, for example, Alzheimer's disease, by known cognitive diagnostic methods, and may include preserved tissue sections from tissue archives. The measurement means of step (c) suitable for the method of the present invention comprises measuring changes in the quantity of intracellular protein, or cell surface protein. Immunoaffinity or ligand affinity measurement quantitates levels of protein in or on the surface of host cells. Unlabelled α7 nicotinic acetylcholine receptor protein is detected by Western blotting, cell surface detection by fluorescent cell sorting, cell image analysis, and immunoassay employing compounds specific for α7 nicotinic acetylcholine receptor protein. Preferred detection means for cell surface protein include flow cytometry or statistical cell imaging. In both techniques the protein of interest is localized at the cell surface, labeled with a specific fluorescent probe, and detected via the degree of cellular fluorescence. In flow cytometry, the cells are analyzed in a solution, whereas in cellular imaging techniques, a field of cells is compared for relative fluorescence.
The methods of the present invention may be used to measure intracellular α7 nicotinic acetylcholine receptor protein contained within the entoplasmic reticulum, Golgi complex, or vesicles. This method provides that the test sample be pretreated to perforate the cell membranes or to solubilize the cell, for example with a detergent containing solution, both techniques are well known in the art. When the cell membranes are perforated, the compound enters the cell and specifically interacts with the cc7 nicotinic acetylcholine receptor in the compartments previously described. Cell extracts provide soluble α7 nicotinic acetylcholine receptor protein that may be measured by the methods described herein, preferably by ELISA utilizing a chemiluminescent detection system. The method to detect intracellular α7 nicotinic acetylcholine receptor protein comprises the steps: (a) obtaining a test sample from a subject wherein the test sample comprises a cell, said cell expressing α7 nicotinic acetylcholine receptor protein in healthy individuals;
(b) contacting the test sample with a membrane perforating agent;
(c) contacting the test sample with a labeled compound capable of specific interaction with the α7 nicotinic acetylcholine receptor; and
(d) measuring the binding of the compound to α7 nicotinic acetylcholine receptor protein as an indication of α7 nicotinic acetylcholine receptor protein in the test sample.
Membrane perforating agents are well known in the art, and are used, for instance to perforate lymphocytic cells to analyze intracellular components using flow cytometry. These agents are commercially available, for example, by Ortho Clinical
Diagnostics under the name PERMEAFIX™.
A particular assay of the present invention comprises binding protein assay methods using a compound capable of specific interaction with α7 nicotinic acetylcholine receptor protein to detect changes in the level of 7 nicotinic acetylcholine receptor protein. Preferably the compound is an antibody to α7 nicotinic acetylcholine receptor protein. The preferred method to detect α7 nicotinic acetylcholine receptor protein comprises the steps: (a) obtaining a test sample from a subject wherein the test sample comprises a cell, said cell expressing α7 nicotinic acetylcholine receptor protein in healthy individuals;
(b) contacting the test sample with a labeled antibody capable of specific interaction with the α7 nicotinic acetylcholine receptor, wherein the antibody becomes a bound antibody or an unbound antibody;
(c) removing the unbound antibody from the test sample; and (d) measuring the quantity of bound or unbound antibody to indicate changes in the level of α7 nicotinic acetylcholine receptor protein in the test sample.
Particular changes in the level of the oc7 nicotinic acetylcholine receptor protein are either to increase or to decrease in the test sample. The preferred change in the level of the α7 nicotinic acetylcholine receptor protein in lymphocytes, olfactory tissue, and hippocampal tissue is to decrease as an indication of development or worsening of AD in the subject.
The following examples illustrate the present invention without, however, limiting the same thereto.
EXAMPLE 1
Western blot analysis of α7 nicotinic acetylcholine receptor
We analyzed 12 sporadic AD brains (mean age = 73.9 + 1.5, mean postmortem time interval = 11.7 + 1.4 hr) from subjects that were clinically diagnosed according to the criteria defined by The National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of AD (The National Institute on Aging and Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease. Neurobiol . Aging 1997; 18(4 Suppl.): Sl-2) . These tissues were further characterized by immunohistochemistry to verify the amyloid plaques and neurofibrillary tangles pathology. We compared the protein levels of the α7 nicotinic acetylcholine receptor in these AD brains to those of the control non-demented subjects (n = 12, mean age = 71.6 + 1.4, mean postmortem time interval = 10 ± 2.0 hr) . Equal amounts of hippocampal total protein were subjected to electrophoresis. Western blotting and analysed using anti-α7 nicotinic acetylcholine receptor antibodies (RBI, Fig. 1) . A horseradish peroxidase conjugated secondary antibody was employed in the chemiluminscence detection protocol (Supersignal, Pierce & Warriner) . Figure 1 shows that the amount of α7 nicotinic acetylcholine receptor protein was reduced. The extent of the reduction was measured by densitometry and indicated that the α7 acetylcholine receptor was reduced by 57+5% compared to controls (Table 1, p < 0.04). A reduction was observed in all twelve AD brain samples tested.
Table 1
Postmortem brain
Diagnosis Age Gender Post Mortem interval (hr)
Al AD 78 Female 9.4
A2 AD 72 female 17.7
A3 AD 73 female 14.1
A4 AD 76 female 15.5
A5 AD 73 female 3
A6 AD 77 female 15.3
A7 AD 78 male 6.7
A8 AD 75 female 17.5
A9 AD 77 male 6.6
A10 AD 79 male 14.9
All AD 61 male 7.3
A12 AD 68 male 12.6
Cl Control 70 female 18.4
C2 Control 69 male 9.8
C3 Control 70 male 14.9
C4 Control 70 male 14.3
C5 Control 76 male 5.4
C6 Control 81 male 2.4
C7 Control 68 male 4.1
C8 Control 77 male 2.3
C9 Control 68 male 12
CIO Control 70 male 6.3
Cll Control 64 female 5.4
C12 Control 75 female 3.5
Postmortem brains were obtained from Harvard Brain Tissue Resource Center at McLean Hospital (Belmont, MA) and Analytical Biological Services, Inc. (Wilmington, DE). The mean ages of the subjects for AD and controls were 73.9 ± 1.5 and 71.6 ± 1.4, respectively. The postmortem interval for AD and control subjects were 11.7 ± 1.4 hr and 10.0 ± 2.0 hr, respectively.

Claims

WHAT IS CLAIMED IS:
1. A method of diagnosis, determining prognosis, progression, or monitoring therapeutic efficacy of any intervention or treatment of neurodegenerative disease comprising:
(a) obtaining a test sample from a subject wherein the test sample comprises a cell, said cell expressing α7 nicotinic acetylcholine receptor protein; (b) contacting the test sample with a compound capable of specific interaction with the α7 nicotinic acetylcholine receptor protein; and
(c) measuring the binding of the compound to α7 nicotinic acetylcholine receptor protein as an indication of α7 nicotinic acetylcholine receptor protein in the test sample.
2. The method of claim 1 wherein the neurodegenerative disease is Alzheimer's disease.
3. The method of claim 1 wherein the compound is a labeled compound.
4. The method of claim 1, 2 or 3 further comprising adding a step (d) of comparing changes in the level of α7 nicotinic acetylcholine receptor protein in the test sample with a normal sample from a subject known to lack neurodegenerative disease.
5. The method of claim 1, 2 or 3 wherein the test sample comprises a cell selected from the group consisting of circulating lymphocytes, olfactory neuroepithelial neuronal cell bodies or their neuronal processes, and hippocampal cells.
6. The method of claim 1 or 2 wherein the compound is selected from the group consisting of Aβ1-40 peptide, Aβ1-42 peptide, Aβ1-43 peptide, a monoclonal antibody, and a polyclonal antibody.
7. The method of claim 1, 2, or 3 wherein the change is a decrease in the level of the α7 nicotinic acetylcholine receptor protein.
8. A method of diagnosis, determining prognosis, progression, or monitoring the therapeutic efficacy of any intervention or treatment of Alzheimer's disease comprising:
(a) obtaining a test sample from a subject wherein the test sample comprises a cell selected from the group consisting of circulating lymphocytes, olfactory neuroepithelial neuronal cell bodies or their neuronal processes, or hippocampal cells, said cell expressing α7 nicotinic acetylcholine receptor protein in healthy individuals;
(b) contacting the test sample with an antibody capable of specific interaction with the α7 nicotinic acetylcholine receptor protein; and
(c) measuring the binding of the antibody to the α7 nicotinic acetylcholine receptor protein as an indication of decreases in the level of α7 nicotinic acetylcholine receptor protein in the test sample.
9. The method of claim 8 further comprises adding a step (d) of comparing changes in the level of a.1 acetylcholine receptor protein in the test sample with a normal sample, from a subject known to lack neurodegenerative and neurological diseases.
10. A method to detect intracellular ct7 nicotinic acetylcholine receptor protein in an Alzheimer's Disease subject which comprises the steps: (a) obtaining a test sample from a subject wherein the test sample comprises a cell, said cell expressing α7 nicotinic acetylcholine receptor protein in healthy individuals;
(b) contacting the test sample with a membrane perforating agent ;
(c) contacting the test sample with a labeled compound capable of specific interaction with the α7 nicotinic acetylcholine receptor; and
(d) measuring the binding of the compound to α7 nicotinic acetylcholine receptor protein as an indication of α7 nicotinic acetylcholine receptor protein in the test sample.
11. An immunoassay method to detect oc7 nicotinic acetylcholine receptor protein in an Alzheimer's Disease subject which comprises the steps:
(a) obtaining a test sample from a subject wherein the test sample comprises a cell, said cell expressing α7 nicotinic acetylcholine receptor protein in healthy individuals;
(b) contacting the test sample with a labeled antibody capable of specific interaction with the α7 nicotinic acetylcholine receptor, wherein the antibody becomes a bound antibody or an unbound antibody;
(c) removing the unbound antibody from the test sample; and
(d) measuring the quantity of bound or unbound antibody to indicate changes in the level of α7 nicotinic acetylcholine receptor protein in the test sample.
EP00982134A 1999-12-01 2000-11-16 Method of diagnosing neurodegenerative disease Withdrawn EP1233979A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16823899P 1999-12-01 1999-12-01
US168238P 1999-12-01
PCT/US2000/031467 WO2001040261A1 (en) 1999-12-01 2000-11-16 Method of diagnosing neurodegenerative disease

Publications (1)

Publication Number Publication Date
EP1233979A1 true EP1233979A1 (en) 2002-08-28

Family

ID=22610681

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00982134A Withdrawn EP1233979A1 (en) 1999-12-01 2000-11-16 Method of diagnosing neurodegenerative disease

Country Status (5)

Country Link
EP (1) EP1233979A1 (en)
JP (1) JP2003530542A (en)
AU (1) AU1920401A (en)
CA (1) CA2393004A1 (en)
WO (1) WO2001040261A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064250A1 (en) 2008-12-04 2010-06-10 Yeda Research And Development Co. Ltd. Compositions and methods for diagnosing and treating cancer and neurodegenerative diseases related to beclin-1

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (en) 2001-12-27 2003-07-10 Bayer Ag 2-heteroaryl carboxamides
AU2003276107A1 (en) * 2003-04-24 2004-11-19 Universitat Zurich Method of monitoring immunotherapy
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
PL2889033T3 (en) 2008-11-19 2018-10-31 Forum Pharmaceuticals Inc. Treatment of negative symptoms of schizophrenia with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
US20110301093A1 (en) 2009-05-06 2011-12-08 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Compositions and methods for diagnosing and treating cancer and neurodegenerative diseases related to beclin-1
MX2012013345A (en) 2010-05-17 2013-02-11 Envivo Pharmaceuticals Inc A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]th iophene-2-carboxamide hydrochloride monohydrate.
CN103180321A (en) 2010-09-23 2013-06-26 Abbvie公司 Monohydrate of azaadamantane derivative
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
EP2872899B1 (en) * 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patient
US10282875B2 (en) 2015-12-11 2019-05-07 International Business Machines Corporation Graph-based analysis for bio-signal event sensing
JP2022538955A (en) 2019-03-19 2022-09-07 ケンブリッジ コグニション リミテッド Methods and Uses of Diagnosis and Recommendation of Treatments for Mental Disorders
KR102246021B1 (en) * 2019-10-10 2021-04-29 연세대학교 산학협력단 A composition for diagnosing of fibrosis and using thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0140261A1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064250A1 (en) 2008-12-04 2010-06-10 Yeda Research And Development Co. Ltd. Compositions and methods for diagnosing and treating cancer and neurodegenerative diseases related to beclin-1
EP2383294A1 (en) 2008-12-04 2011-11-02 Yeda Research And Development Co. Ltd. Compositions and methods for diagnosing and treating cancer and neurodegenerative diseases related to beclin-1
EP2385071A1 (en) 2008-12-04 2011-11-09 Yeda Research And Development Co. Ltd. Compositions and methods for diagnosing and treating cancer and neurodegenerative diseases related to beclin-1

Also Published As

Publication number Publication date
CA2393004A1 (en) 2001-06-07
JP2003530542A (en) 2003-10-14
AU1920401A (en) 2001-06-12
WO2001040261A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
EP2031398B1 (en) Alzheimer&#39;s disease-specific alterations of the ERK1/ERK2 phosphorylation ratio as Alzheimer&#39;s disease-specific molecular biomarkers (ADSMB)
Dickson et al. Correlations of synaptic and pathological markers with cognition of the elderly
Motter et al. Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
US9797913B2 (en) Alzheimer&#39;s disease-specific alterations of the ERK1/ERK2 phosphorylation ratio-alzheimer&#39;s disease-specific molecular biomarkers (ADSMB)
DE602004011931T2 (en) PRELIMINARY PROCEDURE, DIAGNOSIS AND COMPARATIVE DIAGNOSIS OF ALZHEIMER
EP1934618B1 (en) Alzheimer&#39;s disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer&#39;s disease-specific molecular biomarkers (adsmb)
US20120196300A1 (en) Neurodegenerative Markers for Psychiatric Conditions
EP1233979A1 (en) Method of diagnosing neurodegenerative disease
EP2052255A2 (en) Methods of determining levels of free amino acids and dipeptides and diagnosing alzheimer&#39;s diseases
US9377472B2 (en) Biological complex specific for Alzheimer&#39;s disease detection in vitro and use thereof
US20020006627A1 (en) Method for diagnosis of Alzheimer&#39;s disease
Zhao et al. Upregulation of Aβ42 in the brain and bodily fluids of rhesus monkeys with aging
US20030092613A1 (en) Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
US20210270847A1 (en) Protein and peptide biomarkers for traumatic injury to the central nervous system
Hampel et al. Biomarkers in blood and cerebrospinal fluid
CA2720621A1 (en) Alzheimer&#39;s disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer&#39;s disease-specific molecular biomarkers (adsmb)
EP3765854A1 (en) Markers of synaptopathy in neurodegenerative disease
EP4321869A1 (en) Biomarker for neurodegenerative diseases comprising glycotoxin, specific protein bound to glycotoxin, or glycotoxin-specific protein complex
US20080221042A1 (en) Alzheimer&#39;s disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer&#39;s disease-specific molecular biomarkers (ADSMB)
da Silva Correia Optimization of the RT-QuIC in prion disease diagnostic
US20120196307A1 (en) Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
Schooneboom et al. Cerebrospinal fluid markers for the diagnosis of Alzheimer’s disease
Mueller et al. IDENTIFICATION OF SERUM BIOMARKER CANDIDATES FOR ALZHEIMER'S DISEASE1
Gillespie The Alzheimer's amyloid beta protein: A study of the processes involved in its production and clearance

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020606

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20030603